Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)

被引：10

作者：

Perrot, Aurore ^{[1
]}

Lauwers-Cances, Valerie ^{[2
]}

Touzeau, Cyrille ^{[3
]}

Decaux, Olivier ^{[4
]}

Hulin, Cyrille ^{[5
]}

Macro, Magaret ^{[6
]}

Stoppa, Anne-Marie ^{[7
]}

Chretien, Marie Lorraine ^{[8
]}

Karlin, Lionel ^{[9
]}

Mariette, Clara ^{[10
]}

Jacquet, Caroline ^{[11
]}

Roussel, Murielle ^{[12
]}

Guillemot, Coralie ^{[13
]}

Devlamynck, Laure ^{[2
]}

Avet-Loiseau, Herve ^{[14
]}

Moreau, Philippe ^{[15
]}

Attal, Michel ^{[16
]}

机构：

[1] Ctr Hosp Univ Toulouse, Serv Hematol, Toulouse, France

[2] CHU Toulouse, serv Epidemiol, USMR, Toulouse, France

[3] CHU Nantes, Hematol, Ctr Rech Cancerol & Immunol Nantes Angers CRCINA, Nantes, France

[4] CHU Rennes, Serv Hematol, Rennes, France

[5] Hop Haut Leveque, Univ Hosp, Pessac, France

[6] Ctr Hosp Univ CHU Caen, Caen, France

[7] Inst Paoli Calmettes, Marseille, France

[8] CHU Dijon, Serv Hematol Clin, Dijon, France

[9] Univ Claude Bernard Lyon 1, CHU Lyon Sud, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[10] CHU Grenoble, Serv Hematol, Grenoble, France

[11] CHRU Nancy, Vandoeuvre Les Nancy, France

[12] CHU Limoges, Hematol, Limoges, France

[13] IUCT Oncopole, Pharm Unite Essais Clin, Toulouse, France

[14] UPS, CHU Toulouse, Unite Genom Myelome, IUCT Oncopole, Toulouse, France

[15] CHU Nantes, Nantes, France

[16] Inst Univ Canc Toulouse Oncopole, Toulouse, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

464

引用

页数：5

共 50 条

[41] MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)
Kull, M.
Grosicki, S.
Yeh, S. -P.
Huang, J. S. Y.
Byun, J. M.
DiRienzo, C.
Viqueira, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 314 - 314
[42] MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
Grosicki, Sebastian
Yeh, Su-Peng
Huang, Jeffrey S. Y.
Byun, Ja Min
DiRienzo, Christine
Viqueira, Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China
Fu, Chengcheng
Wang, Jing
Yan, Lingzhi
Jin, Song
Shang, Jingjing
Shi, Xiaolan
Yao, Weiqin
Yan, Zhi
Wu, De-Pei
BLOOD, 2023, 142
[44] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
Moreau, Philippe
Facon, Thierry
Usmani, Saad
Bahlis, Nizar Jacques
Raje, Noopur
Plesner, Torben
Orlowski, Robert Z.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Kumar, Shaji K.
BLOOD, 2022, 140 : 7297 - 7300
[45] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
Moreau, P.
Facon, T.
Usmani, S. Z.
Bahlis, N.
Raje, N.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Wang, G.
Krevvata, M.
Carson, R.
Borgsten, F.
Kumar, S. K.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 238 - 238
[46] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
Moreau, P.
Facon, T.
Usmani, S. Z.
Bahlis, N.
Raje, N.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Pei, H.
Krevvata, M.
Carson, R.
Borgsten, F.
Kumar, S. K.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 316 - 317
[47] Daratumumab (DARA) plus Bortezomib/ Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study
Moreau, Philippe
Hulin, Cyrille
Perrot, Aurore
Arnulf, Bertrand
Belhadj, Karim
Benboubker, Lotfi
Zweegman, Sonja
Caillon, Helene
Caillot, Denis
Avet-Loiseau, Herve
Delforge, Michel
Dejoie, Thomas
Facon, Thierry
Sonntag, Cecile
Fontan, Jean
Mohty, Mohamad
Jie, Kon-Siong
Karlin, Lionel
Kuhnowski, Frederique
Lambert, Jerome
Leleu, Xavier
Macro, Margaret
Orsini-Piocelle, Frederique
Roussel, Murielle
de Colella, Jean Marc Schiano
van de Donk, Niels W. C. J.
Wuilleme, Soraya
Broijl, Annemiek
Touzeau, Cyrille
Tiab, Mourad
Marolleau, Jean-Pierre
Meuleman, Nathalie
Vekemans, Marie-Christiane
Westerman, Matthijs
Klein, Saskia K.
Levin, Mark-David
Offner, Fritz
Escoffre-Barbe, Martine
Eveillard, Jean-Richard
Garidi, Reda
Hua, Winnie
Wang, Jianping
Tuozzo, Alba
de Boer, Carla J.
Rowe, Melissa
Vanquickelberghe, Veronique
Carson, Robin
Vermeulen, Jessica
Corre, Jill
Sonneveld, Pieter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S560 - S561
[48] Carfilzomib, lenalidomide and dexamethasone (KRd) versus elotuzumab-KRd as induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma: post-induction IMWG and MRD response of a randomized multicenter study
Knop, S.
Kull, M.
Kroenke, J.
Drewniok, P.
Schaefer-Eckart, K.
von, Metzler I.
Wolleschak, D.
Kimmig, C.
Greiner, J.
Boettcher, S.
Dechow, T.
Hentrich, M.
Khandanpour, C.
Shumilov, E.
Naumann, R.
Seggewiss-Bernhardt, R.
Hackanson, B.
Wang, S. -Y.
Salwender, H.
Sormann, S.
Stuebig, T.
Brueggemann, M.
Einsele, H.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 58 - 59
[49] Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide plus Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)
Facon, Thierry
Dimopoulos, Meletios A.
Dispenzieri, Angela
Catalano, John V.
Belch, Andrew R.
Hulin, Cyrille
Cavo, Michele
Pinto, Antonella
Weisel, Katja
Ludwig, Heinz
Bahlis, Nizar J.
Banos, Anne
Tiab, Mourad
Delforge, Michel
Cavenagh, James D.
Geraldes, Catarina
Lee, Je-Jung
Chen, Christine I.
Oriol, Albert
De La Rubia, Javier
Qiu, Lugui
White, Darrell J.
Binder, Daniel
Anderson, Kenneth C.
Moreau, Philippe
Attal, Michel
Knight, Robert
Chen, Guang
Van Oostendorp, Jason
Jacques, Christian J.
Ervin-Haynes, Annette
Benboubker, Lofti
BLOOD, 2013, 122 (21)
[50] GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years
Mateos, Maria-Victoria
Paiva, Bruno
Cedena Romero, Maria Teresa
Puig, Noemi
Sureda Balari, Anna Maria
Oriol, Albert
Ocio, Enrique M.
Rosinol, Laura
Gonzalez-Montes, Yolanda
Jose Bargay, Juan
Gonzalez Garcia, Esther
Hernandez Garcia, Miguel Teodoro
Ramirez, Angel
Suarez-Cabrera, Alexia
Blanchard, Maria-Jesus
Garzon, Sebastian
Casado Montero, Luis Felipe
Cabanas Perianes, Valentin
Perez De Oteyza, Jaime
Gironella, Mercedes
Martinez-Lopez, Joaquin
Ana-Isabel-Teruel
Delgado, Pilar
Prieto, Elena
Lahuerta Palacios, Juan Jose
Blade, Joan
San Miguel, Jesus
BLOOD, 2023, 142

← 1 2 3 4 5 →